Sign In
Buy NKGN
$0.0600
+0 (+0%)
At Close: Jun 03, 2026
New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer's disease.
SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commerci
Pooled analyses in patients with moderate Alzheimer's show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mil
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
08:05am, Tuesday, 10'th Mar 2026
SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commerci
Head to Head Contrast: NKGen Biotech (NYSE:NKGN) and SQZ Biotechnologies (NYSE:SQZ)
01:11am, Sunday, 08'th Feb 2026
Profitability This table compares NKGen Biotech and SQZ Biotechnologies' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ)
01:26am, Monday, 02'nd Feb 2026
Profitability This table compares SQZ Biotechnologies and NKGen Biotech's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets SQZ Biotechnologies -369.96%
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D.
08:05am, Thursday, 22'nd Jan 2026
Dr. Miller's appointment further enhances NKGen's scientific and clinical advisory capabilities as the Company advances its research in Alzheimer's and other related neurodegenerative diseases Dr. Mil
Analyzing Genocea Biosciences (NASDAQ:GNCA) and NKGen Biotech (NYSE:NKGN)
02:00am, Thursday, 11'th Dec 2025
Profitability This table compares Genocea Biosciences and NKGen Biotech's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Genocea Biosciences N/A -182
Sorrento Therapeutics (NASDAQ:SRNE) versus NKGen Biotech (NYSE:NKGN) Head-To-Head Review
01:16am, Wednesday, 19'th Nov 2025
Institutional and Insider Ownership 0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 2.6% o
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market
08:05am, Thursday, 09'th Oct 2025
SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercia
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology
08:05am, Monday, 06'th Oct 2025
SANTA ANA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercia
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum
08:05am, Thursday, 18'th Sep 2025
SANTA ANA, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commerci
SANTA ANA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commerci
NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit
08:00am, Wednesday, 06'th Aug 2025
SANTA ANA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercia
SANTA ANA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercia
